Clinical trial results:
A 52-Week, Phase 3, Randomized, Active Comparator and Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222 / MK-3222), Followed by an Optional Long Term Safety Extension Study, in Subjects With Moderate-to-Severe Chronic Plaque Psoriasis (Protocol No. MK-3222-011)

Summary

EudraCT number	2012-001377-88
Trial protocol	DE HU AT BE CZ IT NL DK
Global end of trial date	26 October 2021

Results information

Result version number	v2 (current)
This version publication date	21 June 2026
First version publication date	30 June 2023
Version creation reason	• New data added to full data set Addition of extension study data

Trial information

Trial identification

Sponsor protocol code	MK-3222-011

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01729754
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Sun Pharmaceutical Industries Limited
Sponsor organisation address	Sun House, 201 B/1, Western Express Highway, Goregaon (E), Mumbai, India, 400063
Public contact	Head-Clinical Development, Sun Pharmaceutical Industries Limited, Clinical.Trial@sunpharma.com
Scientific contact	Head-Clinical Development, Sun Pharmaceutical Industries Limited, Clinical.Trial@sunpharma.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	28 September 2015
Is this the analysis of the primary completion data?	Yes
Primary completion date	28 September 2015
Global end of trial reached?	Yes
Global end of trial date	26 October 2021
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

Primary Efficacy Objective: To assess the efficacy of tildrakizumab (SCH 900222/MK-3222), hereafter referred to as tildrakizumab (MK-3222), compared to placebo in the treatment of moderate-to-severe chronic plaque psoriasis as measured by the proportion of subjects with at least 75% improvement in the Psoriasis Area and Severity Index from baseline (PASI 75 response) and the proportion of subjects with a Physician's Global Assessment (PGA) score of "clear" or "minimal" with at least a 2 grade reduction from baseline at Week 12.

Primary Safety/Tolerability Objective: To assess the safety/tolerability of tildrakizumab (MK-3222) in subjects with moderate-to-severe chronic plaque psoriasis at Week 12.

Protection of trial subjects:

The following measures are taken within the study for the protection of the trial subjects:
-The investigator or sub-investigator to stop treatment in any case in which emerging effects are of unacceptable risk to the individual subject.
-Subjects were free to withdraw his/her consent at any time without giving or stating any reason
-All subjects screened for presence of latent or untreated TB infections, HIV, hepatitis B surface antigen, hepatitis C virus, chronic disease, organ dysfunction, use of prohibited medications and presence of any other such conditions to ensure to minimize the potential risk to study subjects prior to enrollment
-Every subject will be monitored for the occurrence of SAEs immediately after the subject has signed informed consent form
-Each subject will be followed up for adverse events for 20 weeks after the last visit in the treatment period.

Protocol was developed in collaboration with a Scientific Advisory Committee (SAC).
The SAC comprised of both Sponsor and non-Sponsor scientific experts who provided input with respect to trial design, interpretation of trial results and subsequent peer reviewed scientific publications; all subjects signed ICF and study procedures were initiated after voluntary written ICF was obtained; study protocol and essential documents were approved by ECs and RAs; an external DMC made recommendations to the Sponsor regarding steps to ensure both subject safety and the continued ethical integrity of the trial safety, DMC also considered the overall risk and benefit to trial participants and recommend to the Sponsor if the trial should continue in accordance with the protocol; An Executive Oversight Committee (EOC) comprising of members of Sponsor Senior Management received and decide upon any recommendations made by the external DMC regarding the trial.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	14 December 2012
Long term follow-up planned	Yes
Long term follow-up rationale	Safety
Long term follow-up duration	4 Years
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Netherlands: 7
Country: Number of subjects enrolled	Poland: 97
Country: Number of subjects enrolled	Austria: 13
Country: Number of subjects enrolled	Belgium: 36
Country: Number of subjects enrolled	Czech Republic: 5
Country: Number of subjects enrolled	Denmark: 11
Country: Number of subjects enrolled	France: 43
Country: Number of subjects enrolled	Germany: 401
Country: Number of subjects enrolled	Hungary: 27
Country: Number of subjects enrolled	Italy: 50
Country: Number of subjects enrolled	Israel: 4
Country: Number of subjects enrolled	Canada: 94
Country: Number of subjects enrolled	United States: 302
Worldwide total number of subjects	1090
EEA total number of subjects	690

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	993
From 65 to 84 years	97
85 years and over	0

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

A total of 1372 subjects were screened for the study, of which 282 subjects were not randomized into the study.

Period 1

Period 1 title	Base Study - Part 1 (Day 1 to Week 12)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Carer, Assessor

Arms

Are arms mutually exclusive?	Yes
Arm title	Placebo

Arm description:

Tildrakizumab placebo SC at Weeks 0 and 4 and etanercept placebo SC twice weekly

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

Matching placebo to tildrakizumab/etanercept administered SC

Arm title	Tildrakizumab 100 mg

Arm description:

Tildrakizumab 100 mg SC at Weeks 0 and 4 and etanercept placebo SC twice weekly

Arm type	Experimental
Investigational medicinal product name	Tildrakizumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

Tildrakizumab 100 mg administered SC.

Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

Matching placebo to tildrakizumab/etanercept administered SC

Arm title	Tildrakizumab 200 mg

Arm description:

Tildrakizumab 200 mg SC at Weeks 0 and 4 and etanercept placebo SC twice weekly

Arm type	Experimental
Investigational medicinal product name	Tildrakizumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:
Tildrakizumab 200 mg administered SC.

Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:
Matching placebo to tildrakizumab/etanercept administered SC

Arm title	Etanercept 50 mg

Arm description:
Etanercept 50 mg SC twice weekly and tildrakizumab placebo SC at Weeks 0 and 4

Arm type	Active comparator
Investigational medicinal product name	Etanercept
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:
Etanercept 50 mg administered SC

Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:
Matching placebo to tildrakizumab/etanercept administered SC

Number of subjects in period 1	Placebo	Tildrakizumab 100 mg	Tildrakizumab 200 mg
Started	156	307	314
Completed	142	295	300
Not completed	14	12	14
Consent withdrawn by subject	5	7	5
Physician decision	-	-	-
Non-Compliance with Study Drug	-	-	1
Adverse event, non-fatal	2	1	2
Progressive Disease	-	-	-
Pregnancy	-	1	-
Protocol Violation	1	1	2

Other Protocol Specified Criteria	1	-	2
Lost to follow-up	3	2	1
Lack of efficacy	2	-	1

Number of subjects in period 1	Etanercept 50 mg
Started	313
Completed	289
Not completed	24
Consent withdrawn by subject	6
Physician decision	4
Non-Compliance with Study Drug	-
Adverse event, non-fatal	5
Progressive Disease	1
Pregnancy	1
Protocol Violation	-
Other Protocol Specified Criteria	4
Lost to follow-up	3
Lack of efficacy	-

Period 2

Period 2 title	Base period- Part 2 (Week 12 to Week 28)
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Carer, Assessor

Arms

Are arms mutually exclusive?	No
Arm title	Placebo (Part 1) to Tildrakizumab 100 mg (Part 2)

Arm description:

Tildrakizumab 100 mg SC at Weeks 12, and 16 and etanercept placebo SC once weekly.

Treatment group included Part 1 placebo subjects re-randomized to tildrakizumab 100 mg at Week 12.

Arm type	Experimental
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

Matching placebo to tildrakizumab/etanercept administered SC

Investigational medicinal product name	Tildrakizumab
Investigational medicinal product code	
Other name	

Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

Tildrakizumab 100 mg administered SC.

Arm title	Placebo (Part 1) to Tildrakizumab 200 mg (Part 2)

Arm description:

Tildrakizumab 200 mg SC at Weeks 12 and 16 and etanercept placebo SC once weekly

Treatment group included Part 1 placebo subjects re-randomized to tildrakizumab 200 mg at Week 12

Arm type	Experimental
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

Matching placebo to tildrakizumab/etanercept administered SC

Investigational medicinal product name	Tildrakizumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

Tildrakizumab 200 mg administered SC.

Arm title	Tildrakizumab 100 mg (Part 1 and 2)

Arm description:

Tildrakizumab 100 mg SC at Week 16, tildrakizumab placebo SC at Week 12, and etanercept placebo SC once weekly
Treatment group included Part 1 tildrakizumab 100 mg treated subjects who continued on the same dose (tildrakizumab 100 mg) in Part 2.

Arm type	Experimental
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

Matching placebo to tildrakizumab/etanercept administered SC

Investigational medicinal product name	Tildrakizumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

Tildrakizumab 100 mg administered SC.

Arm title	Tildrakizumab 200 mg (Part 1 and 2)

Arm description:

Tildrakizumab 200 mg SC at Week 16, tildrakizumab placebo SC at Week 12, and etanercept placebo SC once weekly.
Treatment group included Part 1 tildrakizumab 200 mg treated subjects who continued on the same dose (tildrakizumab 200 mg) in Part 2.

Arm type	Experimental

Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

Matching placebo to tildrakizumab/etanercept administered SC

Investigational medicinal product name	Tildrakizumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

Tildrakizumab 200 mg administered SC.

Arm title	Etanercept 50 mg (Part 1 and 2)

Arm description:

Etanercept 50 mg SC once weekly and tildrakizumab placebo at Week 12 and Week 16.
Treatment group included Part 1 etanercept subjects who continued on the same dose (etanercept 50 mg) in Part 2.

Arm type	Active comparator
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

Matching placebo to tildrakizumab/etanercept administered SC

Investigational medicinal product name	Etanercept
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

Etanercept 50 mg administered SC

Number of subjects in period 2	Placebo (Part 1) to Tildrakizumab 100 mg (Part 2)	Placebo (Part 1) to Tildrakizumab 200 mg (Part 2)	Tildrakizumab 100 mg (Part 1 and 2)
Started	70	72	294
Completed	66	69	289
Not completed	4	3	5
Consent withdrawn by subject	1	1	2
Non-Compliance with Study Drug	-	-	-
Adverse event, non-fatal	1	-	-
Pregnancy	-	-	1
Other Protocol Specified Criteria	-	1	-
Lost to follow-up	-	1	2

Lack of efficacy	2	-	-

Number of subjects in period 2	Tildrakizumab 200 mg (Part 1 and 2)	Etanercept 50 mg (Part 1 and 2)
Started	300	289
Completed	294	277
Not completed	6	12
Consent withdrawn by subject	3	4
Non-Compliance with Study Drug	-	1
Adverse event, non-fatal	2	2
Pregnancy	-	1
Other Protocol Specified Criteria	1	-
Lost to follow-up	-	2
Lack of efficacy	-	2

Period 3

Period 3 title	Base period- Part 3 (Week 28 to Week 52)
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Carer, Assessor

Arms

Are arms mutually exclusive?	No
Arm title	Placebo (Part 1)/Tildrakizumab 100 mg (Parts 2 & 3)

Arm description:

Tildrakizumab 100 mg SC at Weeks 28, 40, and 52 and tildrakizumab placebo SC at Weeks 32, 36, and 48.

Treatment group included: Part 1 placebo subjects re-randomized to the tildrakizumab 100 mg in Part 2 who continued on the same
dose (tildrakizumab 100 mg) in Part 3.

Arm type	Experimental
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

Matching placebo to tildrakizumab/etanercept administered SC

Investigational medicinal product name	Tildrakizumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

Tildrakizumab 100 mg administered SC.

Arm title	Tildrakizumab 100 mg (Part 1,2 and 3)

Arm description:

Tildrakizumab 100 mg SC at Weeks 28, 40, and 52 and tildrakizumab placebo SC at Weeks 32, 36, and 48

Treatment group included: subjects originally randomized to tildrakizumab 100 mg in Part 1 who were responders or partial responders at Week 28 who continued on the same dose in Part 3.

Arm type	Experimental
Investigational medicinal product name	Tildrakizumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

Tildrakizumab 100 mg administered SC.

Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

Matching placebo to tildrakizumab/etanercept administered SC

Arm title	Tildrakizumab 100 mg (Parts 1 & 2)/ 200 mg (Part 3)

Arm description:

Tildrakizumab 200 mg SC at Weeks 28, 40, and 52 and tildrakizumab placebo SC at Weeks 32, 36, and 48

Treatment group included: subjects originally randomized to tildrakizumab 100 mg in Part 1 who were partial responders at Week 28 and
were re-randomized at Week 28 to tildrakizumab 200 mg for Part 3.

Arm type	Experimental
Investigational medicinal product name	Tildrakizumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

Tildrakizumab 200 mg administered SC.

Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

Matching placebo to tildrakizumab/etanercept administered SC

Arm title	Placebo (Part 1)/ Tildrakizumab 200 mg (Parts 2 & 3)

Arm description:

Tildrakizumab 200 mg SC at Weeks 28, 40, and 52 and tildrakizumab placebo SC at Weeks 32, 36, and 48
Treatment group included: Part 1 placebo subjects re-randomized to the tildrakizumab 200 mg in Part 2 who continued on the same dose (tildrakizumab 200 mg) in Part 3.

Arm type	Experimental

Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

Matching placebo to tildrakizumab/etanercept administered SC

Investigational medicinal product name	Tildrakizumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

Tildrakizumab 200 mg administered SC.

Arm title	Tildrakizumab 200 mg (Parts 1 & 2)/ 100 mg (Part 3)

Arm description:

Tildrakizumab 100 mg SC at Weeks 28, 40, and 52 and tildrakizumab placebo SC at Weeks 32, 36, and 48

Treatment group included: subjects originally randomized to tildrakizumab 200 mg in Part 1 who were responders at Week 28 and were re-randomized at Week 28 to tildrakizumab 100 mg for Part 3.

Arm type	Experimental
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

Matching placebo to tildrakizumab/etanercept administered SC

Investigational medicinal product name	Tildrakizumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

Tildrakizumab 100 mg administered SC.

Arm title	Tildrakizumab 200 mg (Parts 1, 2, & 3)

Arm description:

Tildrakizumab 200 mg SC at Weeks 28, 40, and 52 and tildrakizumab placebo SC at Weeks 32, 36, and 48.

Treatment group included: subjects originally randomized to tildrakizumab 200 mg in Part 1 who were responders or partial responders at
Week 28 who continued on the same dose in Part 3

Arm type	Experimental
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

Matching placebo to tildrakizumab/etanercept administered SC

Investigational medicinal product name	Tildrakizumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

Tildrakizumab 200 mg administered SC.

Arm title	Etanercept 50 mg (Parts 1 & 2)/ Tildrakizumab 200 mg (Part 3)

Arm description:

Tildrakizumab 200 mg SC at Weeks 32, 36, and 48 and tildrakizumab placebo SC at Weeks 28, 40, and 52.

Treatment group included: subjects originally randomized to etanercept in Part 1 who were non-responders or partial responders at Week 28 and were assigned to tildrakizumab 200 mg in Part 3.

Arm type	Active comparator
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

Matching placebo to tildrakizumab/etanercept administered SC

Investigational medicinal product name	Tildrakizumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

Tildrakizumab 200 mg administered SC.

Investigational medicinal product name	Etanercept
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

Etanercept 50 mg administered SC

Number of subjects in period 3	Placebo (Part 1)/Tildrakizumab 100 mg (Parts 2 &	Tildrakizumab 100 mg (Part 1,2 and 3)	Tildrakizumab 100 mg (Parts 1 & 2)/ 200 mg (Part 3)
Started	66	237	21
Completed	65	224	17
Not completed	1	13	4
Adverse event, serious fatal	-	2	-
Consent withdrawn by subject	-	1	2
Physician decision	-	-	-
Adverse event, non-fatal	-	5	-
Other Protocol Specified Criteria	-	2	-

Lost to follow-up	1	3	-
Lack of efficacy	-	-	2

Number of subjects in period 3	Placebo (Part 1)/ Tildrakizumab 200 mg (Parts 2 & 3)	Tildrakizumab 200 mg (Parts 1 & 2)/ 100 mg (Part 3)	Tildrakizumab 200 mg (Parts 1, 2, & 3)
Started	69	110	170
Completed	66	105	165
Not completed	3	5	5
Adverse event, serious fatal	-	-	-
Consent withdrawn by subject	2	1	4
Physician decision	-	1	-
Adverse event, non-fatal	-	1	-
Other Protocol Specified Criteria	1	-	-
Lost to follow-up	-	2	1
Lack of efficacy	-	-	-

Number of subjects in period 3	Etanercept 50 mg (Parts 1 & 2)/ Tildrakizumab 200 mg (Part 3)
Started	121
Completed	114
Not completed	7
Adverse event, serious fatal	-
Consent withdrawn by subject	-
Physician decision	-
Adverse event, non-fatal	3
Other Protocol Specified Criteria	-
Lost to follow-up	-
Lack of efficacy	4

Period 4	
Period 4 title	Extension Study
Is this the baseline period?	No
Allocation method	Not applicable
Blinding used	Not blinded
Arms	
Are arms mutually exclusive?	Yes

Arm title	Tildrakizumab 100 mg (Extension Study)
Arm description: Tildrakizumab 100 mg every 12 Weeks	
Arm type	Experimental
Investigational medicinal product name	Tildrakizumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection in pre-filled injector, Solution for injection/infusion in pre-filled syringe
Routes of administration	Subcutaneous use
Dosage and administration details: Tildrakizumab 100 mg every 12 Weeks, in either the Pre filled syringe (PFS) or Auto Injector (AI) format	
Arm title	Tildrakizumab 200 mg (extension study)
Arm description: Tildrakizumab 200 mg every 12 Weeks	
Arm type	Experimental
Investigational medicinal product name	Tildrakizumab 200 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection/infusion in pre-filled syringe
Routes of administration	Subcutaneous use
Dosage and administration details: Tildrakizumab 200 mg every 12 Weeks	

Number of subjects in period 4	Tildrakizumab 100 mg (Extension Study)	Tildrakizumab 200 mg (extension study)
Started	381	349
Completed	290	272
Not completed	91	77
Adverse event, serious fatal	3	1
Physician decision	8	11
Consent withdrawn by subject	35	24
Non-Compliance with Study Drug	2	2
Adverse event, non-fatal	14	11
Progressive Disease	-	2
Pregnancy	2	1
Other Protocol Specified Criteria	1	-
Lost to follow-up	15	13
missing completion/discontinuation information	1	1
Lack of efficacy	10	11

Baseline characteristics

Reporting groups	
Reporting group title	Placebo
Reporting group description:	
Tildrakizumab placebo SC at Weeks 0 and 4 and etanercept placebo SC twice weekly	
Reporting group title	Tildrakizumab 100 mg
Reporting group description:	
Tildrakizumab 100 mg SC at Weeks 0 and 4 and etanercept placebo SC twice weekly	
Reporting group title	Tildrakizumab 200 mg
Reporting group description:	
Tildrakizumab 200 mg SC at Weeks 0 and 4 and etanercept placebo SC twice weekly	
Reporting group title	Etanercept 50 mg
Reporting group description:	
Etanercept 50 mg SC twice weekly and tildrakizumab placebo SC at Weeks 0 and 4	

Reporting group values	Placebo	Tildrakizumab 100 mg	Tildrakizumab 200 mg
Number of subjects	156	307	314
Age categorical Units: Subjects			
Adults (18-64 years)	142	280	289
From 65-84 years	14	27	25
Gender categorical Units: Subjects			
Female	44	87	89
Male	112	220	225

Reporting group values	Etanercept 50 mg	Total	
Number of subjects	313	1090	
Age categorical Units: Subjects			
Adults (18-64 years)	282	993	
From 65-84 years	31	97	
Gender categorical Units: Subjects			
Female	91	311	
Male	222	779	

End points

End points reporting groups

Reporting group title	Placebo
Reporting group description:	
Tildrakizumab placebo SC at Weeks 0 and 4 and etanercept placebo SC twice weekly	
Reporting group title	Tildrakizumab 100 mg
Reporting group description:	
Tildrakizumab 100 mg SC at Weeks 0 and 4 and etanercept placebo SC twice weekly	
Reporting group title	Tildrakizumab 200 mg
Reporting group description:	
Tildrakizumab 200 mg SC at Weeks 0 and 4 and etanercept placebo SC twice weekly	
Reporting group title	Etanercept 50 mg
Reporting group description:	
Etanercept 50 mg SC twice weekly and tildrakizumab placebo SC at Weeks 0 and 4	
Reporting group title	Placebo (Part 1) to Tildrakizumab 100 mg (Part 2)
Reporting group description:	
Tildrakizumab 100 mg SC at Weeks 12, and 16 and etanercept placebo SC once weekly. Treatment group included Part 1 placebo subjects re-randomized to tildrakizumab 100 mg at Week 12.	
Reporting group title	Placebo (Part 1) to Tildrakizumab 200 mg (Part 2)
Reporting group description:	
Tildrakizumab 200 mg SC at Weeks 12 and 16 and etanercept placebo SC once weekly Treatment group included Part 1 placebo subjects re-randomized to tildrakizumab 200 mg at Week 12	
Reporting group title	Tildrakizumab 100 mg (Part 1 and 2)
Reporting group description:	
Tildrakizumab 100 mg SC at Week 16, tildrakizumab placebo SC at Week 12, and etanercept placebo SC once weekly Treatment group included Part 1 tildrakizumab 100 mg treated subjects who continued on the same dose (tildrakizumab 100 mg) in Part 2.	
Reporting group title	Tildrakizumab 200 mg (Part 1 and 2)
Reporting group description:	
Tildrakizumab 200 mg SC at Week 16, tildrakizumab placebo SC at Week 12, and etanercept placebo SC once weekly. Treatment group included Part 1 tildrakizumab 200 mg treated subjects who continued on the same dose (tildrakizumab 200 mg) in Part 2.	
Reporting group title	Etanercept 50 mg (Part 1 and 2)
Reporting group description:	
Etanercept 50 mg SC once weekly and tildrakizumab placebo at Week 12 and Week 16. Treatment group included Part 1 etanercept subjects who continued on the same dose (etanercept 50 mg) in Part 2.	
Reporting group title	Placebo (Part 1)/Tildrakizumab 100 mg (Parts 2 & 3)
Reporting group description:	
Tildrakizumab 100 mg SC at Weeks 28, 40, and 52 and tildrakizumab placebo SC at Weeks 32, 36, and 48. Treatment group included: Part 1 placebo subjects re-randomized to the tildrakizumab 100 mg in Part 2 who continued on the same dose (tildrakizumab 100 mg) in Part 3.	
Reporting group title	Tildrakizumab 100 mg (Part 1,2 and 3)
Reporting group description:	
Tildrakizumab 100 mg SC at Weeks 28, 40, and 52 and tildrakizumab placebo SC at Weeks 32, 36, and 48 Treatment group included: subjects originally randomized to tildrakizumab 100 mg in Part 1 who were	

responders or partial responders at Week 28 who continued on the same dose in Part 3.

Reporting group title	Tildrakizumab 100 mg (Parts 1 & 2)/ 200 mg (Part 3)

Reporting group description:

Tildrakizumab 200 mg SC at Weeks 28, 40, and 52 and tildrakizumab placebo SC at Weeks 32, 36, and 48

Treatment group included: subjects originally randomized to tildrakizumab 100 mg in Part 1 who were partial responders at Week 28 and
were re-randomized at Week 28 to tildrakizumab 200 mg for Part 3.

Reporting group title	Placebo (Part 1)/ Tildrakizumab 200 mg (Parts 2 & 3)

Reporting group description:

Tildrakizumab 200 mg SC at Weeks 28, 40, and 52 and tildrakizumab placebo SC at Weeks 32, 36, and 48
Treatment group included: Part 1 placebo subjects re-randomized to the tildrakizumab 200 mg in Part 2 who continued on the same dose (tildrakizumab 200 mg) in Part 3.

Reporting group title	Tildrakizumab 200 mg (Parts 1 & 2)/ 100 mg (Part 3)

Reporting group description:

Tildrakizumab 100 mg SC at Weeks 28, 40, and 52 and tildrakizumab placebo SC at Weeks 32, 36, and 48

Treatment group included: subjects originally randomized to tildrakizumab 200 mg in Part 1 who were responders at Week 28 and were re-randomized at Week 28 to tildrakizumab 100 mg for Part 3.

Reporting group title	Tildrakizumab 200 mg (Parts 1, 2, & 3)

Reporting group description:

Tildrakizumab 200 mg SC at Weeks 28, 40, and 52 and tildrakizumab placebo SC at Weeks 32, 36, and 48.

Treatment group included: subjects originally randomized to tildrakizumab 200 mg in Part 1 who were responders or partial responders at
Week 28 who continued on the same dose in Part 3

Reporting group title	Etanercept 50 mg (Parts 1 & 2)/ Tildrakizumab 200 mg (Part 3)

Reporting group description:

Tildrakizumab 200 mg SC at Weeks 32, 36, and 48 and tildrakizumab placebo SC at Weeks 28, 40, and 52.

Treatment group included: subjects originally randomized to etanercept in Part 1 who were non-responders or partial responders at Week 28 and were assigned to tildrakizumab 200 mg in Part 3.

Reporting group title	Tildrakizumab 100 mg (Extension Study)

Reporting group description:

Tildrakizumab 100 mg every 12 Weeks

Reporting group title	Tildrakizumab 200 mg (extension study)

Reporting group description:

Tildrakizumab 200 mg every 12 Weeks

Primary: Percentage of Participants Achieving a Psoriasis Area Sensitivity Index 75% (PASI-75) Response at Week 12

End point title	Percentage of Participants Achieving a Psoriasis Area Sensitivity Index 75% (PASI-75) Response at Week 12

End point description:

End point type	Primary

End point timeframe:

Week 12

End point values	Placebo	Tildrakizumab 100 mg	Tildrakizumab 200 mg	Etanercept 50 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	156	307	314	313
Units: Percentage of participants				
number (not applicable)	5.8	61.2	65.6	48.2

Statistical analyses

Statistical analysis title	CMH Analysis of PASI 75 at Week 12
Comparison groups	Tildrakizumab 200 mg v Placebo
Number of subjects included in analysis	470
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Cochran-Mantel-Haenszel

Primary: Percentage of Participants with a Physician's Global Assessment (PGA) Score of Clear or Minimal With at Least a 2 Grade Reduction From Baseline at Week 12

End point title	Percentage of Participants with a Physician's Global Assessment (PGA) Score of Clear or Minimal With at Least a 2 Grade Reduction From Baseline at Week 12

End point description:

End point type	Primary

End point timeframe:

Week 12

End point values	Placebo	Tildrakizumab 100 mg	Tildrakizumab 200 mg	Etanercept 50 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	156	307	314	313
Units: Percentage of participants				
number (not applicable)	4.5	54.7	59.2	47.6

Statistical analyses

Statistical analysis title	CMH Analysis of PGA score at Week 12
Comparison groups	Placebo v Tildrakizumab 200 mg
Number of subjects included in analysis	470
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Cochran-Mantel-Haenszel

Secondary: Percentage of Participants Achieving a PASI-75 Response at Week 28

End point title	Percentage of Participants Achieving a PASI-75 Response at Week 28

End point description:

End point type	Secondary

End point timeframe:

Week 28

End point values	Tildrakizumab 100 mg (Part 1 and 2)	Tildrakizumab 200 mg (Part 1 and 2)	Etanercept 50 mg (Part 1 and 2)	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	294	299	289	
Units: Percentage of Participant				
number (not applicable)	73.5	72.6	53.6	

Statistical analyses

Statistical analysis title	CMH Analysis of PASI 75 at Week 28
Comparison groups	Tildrakizumab 100 mg (Part 1 and 2) v Etanercept 50 mg (Part 1 and 2)
Number of subjects included in analysis	583
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Cochran-Mantel-Haenszel

Statistical analysis title	CMH Analysis of PASI 75 at Week 28
Comparison groups	Tildrakizumab 200 mg (Part 1 and 2) v Etanercept 50 mg (Part 1 and 2)

Number of subjects included in analysis	588
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Cochran-Mantel-Haenszel

Secondary: Percentage of Participants Achieving a PASI-90 Response at Week 12

End point title	Percentage of Participants Achieving a PASI-90 Response at Week 12

End point description:

End point type	Secondary

End point timeframe:

Week 12

End point values	Placebo	Tildrakizumab 100 mg	Tildrakizumab 200 mg	Etanercept 50 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	156	307	314	313
Units: Percentage of subjects				
number (not applicable)	1.3	38.8	36.6	21.4

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants achieving a PGA score of "clear" or "minimal", with at least a 2 grade reduction from baseline, at Week 28

End point title	Percentage of Participants achieving a PGA score of "clear" or "minimal", with at least a 2 grade reduction from baseline, at Week 28

End point description:

End point type	Secondary

End point timeframe:

Week 28

End point values	Tildrakizumab 100 mg (Part 1 and 2)	Tildrakizumab 200 mg (Part 1 and 2)	Etanercept 50 mg (Part 1 and 2)	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	294	299	289	
Units: Percentage of Participant				
number (not applicable)	64.6	69.2	45.3	

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants Achieving a PASI-100 Response at Week 12

End point title	Percentage of Participants Achieving a PASI-100 Response at Week 12

End point description:

End point type	Secondary

End point timeframe:

Week 12

End point values	Placebo	Tildrakizumab 100 mg	Tildrakizumab 200 mg	Etanercept 50 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	156	307	314	313
Units: Percentage of Participants				
number (not applicable)	0	12.4	11.8	4.8

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in the DLQI at Week 12

End point title	Change From Baseline in the DLQI at Week 12

End point description:

End point type	Secondary

End point timeframe:

Week 12

End point values	Placebo	Tildrakizumab 100 mg	Tildrakizumab 200 mg	Etanercept 50 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	156	307	312	312
Units: Score on a scale				
least squares mean (confidence interval 95%)	-2.0 (-2.9 to -1.1)	-10.2 (-10.9 to -9.6)	-10.3 (-11.0 to -9.7)	-8.9 (-9.6 to -8.3)

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants With a DLQI Score of 0 or 1 at Week 12

End point title	Percentage of Participants With a DLQI Score of 0 or 1 at Week 12

End point description:

End point type	Secondary

End point timeframe:

Week 12

End point values	Placebo	Tildrakizumab 100 mg	Tildrakizumab 200 mg	Etanercept 50 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	150	296	306	304
Units: Percentage of Participant				
number (not applicable)	8	40.2	47.4	35.5

Statistical analyses

No statistical analyses for this end point

Secondary: Mean Change from Baseline in PASI Score at Week 12 and week 28

End point title	Mean Change from Baseline in PASI Score at Week 12 and week 28

End point description:

End point type	Secondary

End point timeframe:

Week 12 and Week 28

End point values	Placebo	Placebo (Part 1) to Tildrakizumab 100 mg (Part 2)	Tildrakizumab 100 mg	Placebo (Part 1) to Tildrakizumab 200 mg (Part 2)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	142	66	297	68
Units: Scores on a scale				
arithmetic mean (standard deviation)	-3.4 (± 6.77)	-14.5 (± 8.46)	-15.1 (± 7.94)	-17.3 (± 8.46)

End point values	Tildrakizumab 200 mg	Tildrakizumab 100 mg (Part 1 and 2)	Etanercept 50 mg	Tildrakizumab 200 mg (Part 1 and 2)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	302	290	288	293
Units: Scores on a scale				
arithmetic mean (standard deviation)	-15.4 (± 7.77)	-16.5 (± 7.71)	-13.5 (± 8.29)	-17.0 (± 7.81)

End point values	Etanercept 50 mg (Part 1 and 2)			
Subject group type	Reporting group			
Number of subjects analysed	277			
Units: Scores on a scale				
arithmetic mean (standard deviation)	-14.8 (± 7.85)			

Statistical analyses

No statistical analyses for this end point

Secondary: Mean Percent Change from Baseline in PASI Score at Week 12 and Week 28

End point title	Mean Percent Change from Baseline in PASI Score at Week 12 and Week 28

End point description:

End point type	Secondary

End point timeframe:

Week 12 and Week 28

End point values	Placebo	Placebo (Part 1) to Tildrakizumab 100 mg (Part 2)	Tildrakizumab 100 mg	Placebo (Part 1) to Tildrakizumab 200 mg (Part 2)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	142	66	297	68
Units: Percent change				
arithmetic mean (standard deviation)	-17.4 (± 32.95)	-72.9 (± 30.05)	-74.8 (± 28.11)	-84.0 (± 16.89)

End point values	Tildrakizumab 200 mg	Tildrakizumab 100 mg (Part 1 and 2)	Etanercept 50 mg	Tildrakizumab 200 mg (Part 1 and 2)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	302	290	288	293
Units: Percent change				
arithmetic mean (standard deviation)	-78.0 (± 22.31)	-82.5 (± 22.33)	-66.7 (± 30.78)	-85.7 (± 17.44)

End point values	Etanercept 50 mg (Part 1 and 2)			
Subject group type	Reporting group			
Number of subjects analysed	277			
Units: Percent change				
arithmetic mean (standard deviation)	-73.5 (± 24.40)			

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants Achieving a PASI-90 Response at Week 28

End point title	Percentage of Participants Achieving a PASI-90 Response at Week 28

End point description:

End point type	Secondary

End point timeframe:

Week 28

End point values	Tildrakizumab 100 mg (Part 1 and 2)	Tildrakizumab 200 mg (Part 1 and 2)	Etanercept 50 mg (Part 1 and 2)	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	290	293	277	
Units: Percentage of Participant				
number (not applicable)	55.5	57.7	30.7	

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants Achieving a PASI-100 Response at Week 28

End point title	Percentage of Participants Achieving a PASI-100 Response at Week 28

End point description:

End point type	Secondary

End point timeframe:

Week 28

End point values	Tildrakizumab 100 mg (Part 1 and 2)	Tildrakizumab 200 mg (Part 1 and 2)	Etanercept 50 mg (Part 1 and 2)	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	290	293	277	
Units: Percentage of Participant				
number (not applicable)	22.8	27.0	11.2	

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in the DLQI at Week 28

End point title	Change From Baseline in the DLQI at Week 28

End point description:

End point type	Secondary

End point timeframe:

Week 28

End point values	Tildrakizumab 100 mg (Part 1 and 2)	Tildrakizumab 200 mg (Part 1 and 2)	Etanercept 50 mg (Part 1 and 2)	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	294	299	289	
Units: Score on a scale				
least squares mean (confidence interval 95%)	-11.2 (-11.8 to -10.5)	-11.7 (-12.3 to -11.1)	-9.5 (-10.1 to -8.9)	

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants With a DLQI Score of 0 or 1 at Week 28

End point title	Percentage of Participants With a DLQI Score of 0 or 1 at Week 28

End point description:

End point type	Secondary

End point timeframe:

Week 28

End point values	Tildrakizumab 100 mg (Part 1 and 2)	Tildrakizumab 200 mg (Part 1 and 2)	Etanercept 50 mg (Part 1 and 2)	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	290	297	282	
Units: Percentage of participants				
number (not applicable)	54.1	65.0	39.4	

Statistical analyses

No statistical analyses for this end point

Secondary: Proportion of Subjects With PASI 50 Response Over Time Among PASI 50 Responders at Week 52 (Extension Study)

End point title	Proportion of Subjects With PASI 50 Response Over Time Among PASI 50 Responders at Week 52 (Extension Study)

End point description:

End point type	Secondary

End point timeframe:

Week 60

End point values	Tildrakizumab 100 mg (Extension Study)	Tildrakizumab 200 mg (extension study)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	373	341		
Units: Proportion of subjects				
number (not applicable)	0.984	0.985		

Statistical analyses

No statistical analyses for this end point

Secondary: Proportion of Subjects With PASI 50 Response Over Time Among PASI 50 Responders at Week 52 (Extension Study)

End point title	Proportion of Subjects With PASI 50 Response Over Time Among PASI 50 Responders at Week 52 (Extension Study)

End point description:

End point type	Secondary

End point timeframe:

Week 112

End point values	Tildrakizumab 100 mg (Extension Study)	Tildrakizumab 200 mg (extension study)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	346	320		
Units: Proportion of subjects				
number (not applicable)	0.983	0.969		

Statistical analyses

No statistical analyses for this end point

Secondary: Proportion of Subjects With PASI 50 Response Over Time Among PASI 50 Responders at Week 52 (Extension Study)

End point title	Proportion of Subjects With PASI 50 Response Over Time Among PASI 50 Responders at Week 52 (Extension Study)

End point description:

End point type	Secondary

End point timeframe:
Week 172

End point values	Tildrakizumab 100 mg (Extension Study)	Tildrakizumab 200 mg (extension study)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	317	293		
Units: Proportion of subjects				
number (not applicable)	0.991	0.98		

Statistical analyses

No statistical analyses for this end point

Secondary: Proportion of Subjects With PASI 50 Response Over Time Among PASI 50 Responders at Week 52 (Extension Study)

End point title	Proportion of Subjects With PASI 50 Response Over Time Among PASI 50 Responders at Week 52 (Extension Study)

End point description:

End point type	Secondary

End point timeframe:
Week 220

End point values	Tildrakizumab 100 mg (Extension Study)	Tildrakizumab 200 mg (extension study)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	294	277		
Units: Proportion of subjects				
number (not applicable)	0.993	0.993		

Statistical analyses

No statistical analyses for this end point

Secondary: Proportion of Subjects With PASI 50 Response Over Time Among PASI 50 Responders at Week 52 (Extension Study)

End point title	Proportion of Subjects With PASI 50 Response Over Time Among PASI 50 Responders at Week 52 (Extension Study)

End point description:

End point type	Secondary

End point timeframe:

Week 268

End point values	Tildrakizumab 100 mg (Extension Study)	Tildrakizumab 200 mg (extension study)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	102	84		
Units: Proportion of subjects				
number (not applicable)	0.99	1		

Statistical analyses

No statistical analyses for this end point

Secondary: Proportion of Subjects With PASI 50 Response Over Time Among PASI 50 Responders at Week 52 (Extension Study)

End point title	Proportion of Subjects With PASI 50 Response Over Time Among PASI 50 Responders at Week 52 (Extension Study)

End point description:

End point type	Secondary

End point timeframe:

Week 316

End point values	Tildrakizumab 100 mg (Extension Study)	Tildrakizumab 200 mg (extension study)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	47	34		
Units: Proportion of subjects				
number (not applicable)	1	1		

Statistical analyses

No statistical analyses for this end point

Secondary: Proportion of Subjects With PASI 50 Response Over Time Among PASI

50 Responders at Week 52 (Extension Study)

End point title	Proportion of Subjects With PASI 50 Response Over Time Among PASI 50 Responders at Week 52 (Extension Study)

End point description:

End point type	Secondary

End point timeframe:

Week 364

End point values	Tildrakizumab 100 mg (Extension Study)	Tildrakizumab 200 mg (extension study)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	11	9		
Units: Proportion of subjects				
number (not applicable)	1	1		

Statistical analyses

No statistical analyses for this end point

Secondary: Proportion of Subjects With PASI 50 Response Over Time Among PASI 50 Responders at Week 52 (Extension Study)

End point title	Proportion of Subjects With PASI 50 Response Over Time Among PASI 50 Responders at Week 52 (Extension Study)

End point description:

End point type	Secondary

End point timeframe:

Week 396

End point values	Tildrakizumab 100 mg (Extension Study)	Tildrakizumab 200 mg (extension study)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1	0[1]		
Units: Proportion of subjects				
number (not applicable)	1			

Notes:

[1] - No subjects were available for assessment at Week 396; therefore, zero subjects were analyzed.

Statistical analyses

No statistical analyses for this end point

Secondary: Proportion of Subjects With PASI 75 Response Over Time Among PASI 75 Responders at Week 52 (Extension Study) at week 60

End point title	Proportion of Subjects With PASI 75 Response Over Time Among PASI 75 Responders at Week 52 (Extension Study) at week 60

End point description:

End point type	Secondary

End point timeframe:

Week 60

End point values	Tildrakizumab 100 mg (Extension Study)	Tildrakizumab 200 mg (extension study)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	344	303		
Units: Proportion of subjects				
number (not applicable)	0.965	0.937		

Statistical analyses

No statistical analyses for this end point

Secondary: Proportion of Subjects With PASI 75 Response Over Time Among PASI 75 Responders at Week 52 (Extension Study) Week 112

End point title	Proportion of Subjects With PASI 75 Response Over Time Among PASI 75 Responders at Week 52 (Extension Study) Week 112

End point description:

End point type	Secondary

End point timeframe:

Week 112

End point values	Tildrakizumab 100 mg (Extension Study)	Tildrakizumab 200 mg (extension study)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	321	286		
Units: Proportion of subjects				
number (not applicable)	0.919	0.878		

Statistical analyses

No statistical analyses for this end point

Secondary: Proportion of Subjects With PASI 75 Response Over Time Among PASI 75 Responders at Week 52 (Extension Study) at Week 220

End point title	Proportion of Subjects With PASI 75 Response Over Time Among PASI 75 Responders at Week 52 (Extension Study) at Week 220

End point description:

End point type	Secondary

End point timeframe:

Week 220

End point values	Tildrakizumab 100 mg (Extension Study)	Tildrakizumab 200 mg (extension study)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	278	256		
Units: Proportion of subjects				
number (not applicable)	0.932	0.898		

Statistical analyses

No statistical analyses for this end point

Secondary: Proportion of Subjects With PASI 75 Response Over Time Among PASI 75 Responders at Week 52 (Extension Study) at Week 268

End point title	Proportion of Subjects With PASI 75 Response Over Time Among PASI 75 Responders at Week 52 (Extension Study) at Week 268

End point description:

End point type	Secondary

End point timeframe:

Week 268

End point values	Tildrakizumab 100 mg (Extension Study)	Tildrakizumab 200 mg (extension study)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	93	76		
Units: Proportion of subjects				
number (not applicable)	0.946	0.921		

Statistical analyses

No statistical analyses for this end point

Secondary: Proportion of Subjects With PASI 75 Response Over Time Among PASI 75 Responders at Week 52 (Extension Study) at Week 316

End point title	Proportion of Subjects With PASI 75 Response Over Time Among PASI 75 Responders at Week 52 (Extension Study) at Week 316

End point description:

End point type	Secondary

End point timeframe:

Week 316

End point values	Tildrakizumab 100 mg (Extension Study)	Tildrakizumab 200 mg (extension study)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	45	31		
Units: Proportion of subjects				
number (not applicable)	0.956	1		

Statistical analyses

No statistical analyses for this end point

Secondary: Proportion of Subjects With PASI 75 Response Over Time Among PASI 75 Responders at Week 52 (Extension Study) at Week 364

End point title	Proportion of Subjects With PASI 75 Response Over Time Among PASI 75 Responders at Week 52 (Extension Study) at Week 364

End point description:

End point type	Secondary

End point timeframe:

Week 364

End point values	Tildrakizumab 100 mg (Extension Study)	Tildrakizumab 200 mg (extension study)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	11	8		
Units: Proportion of subjects				
number (not applicable)	1	1		

Statistical analyses

No statistical analyses for this end point

Secondary: Proportion of Subjects With PASI 75 Response Over Time Among PASI 75 Responders at Week 52 (Extension Study) at Week 396

End point title	Proportion of Subjects With PASI 75 Response Over Time Among PASI 75 Responders at Week 52 (Extension Study) at Week 396

End point description:

End point type	Secondary

End point timeframe:

Week 396

End point values	Tildrakizumab 100 mg (Extension Study)	Tildrakizumab 200 mg (extension study)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1	0[2]		
Units: Proportion of subjects				
number (not applicable)	1			

Notes:

[2] - No subjects were available for assessment at Week 396; therefore, zero subjects were analyzed.

Statistical analyses

No statistical analyses for this end point

Secondary: Proportion of Subjects With PASI 75 Response Over Time Among PASI 75 Responders at Week 52 (Extension Study) at Week 172

End point title	Proportion of Subjects With PASI 75 Response Over Time Among PASI 75 Responders at Week 52 (Extension Study) at Week 172

End point description:

End point type	Secondary

End point timeframe:

Week 172

End point values	Tildrakizumab 100 mg (Extension Study)	Tildrakizumab 200 mg (extension study)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	299	267		
Units: Proportion of subjects				
number (not applicable)	0.936	0.903		

Statistical analyses

No statistical analyses for this end point

Secondary: Proportion of Subjects With PASI 90 Response Over Time Among PASI 90 Responders at Week 52 (Extension Study) at Week 60

End point title	Proportion of Subjects With PASI 90 Response Over Time Among PASI 90 Responders at Week 52 (Extension Study) at Week 60

End point description:

End point type	Secondary

End point timeframe:

Week 60

End point values	Tildrakizumab 100 mg (Extension Study)	Tildrakizumab 200 mg (extension study)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	261	194		
Units: Proportion of subjects				
number (not applicable)	0.931	0.881		

Statistical analyses

No statistical analyses for this end point

Secondary: Proportion of Subjects With PASI 90 Response Over Time Among PASI 90 Responders at Week 52 (Extension Study) at Week 112

End point title	Proportion of Subjects With PASI 90 Response Over Time Among PASI 90 Responders at Week 52 (Extension Study) at Week 112

End point description:

End point type	Secondary

End point timeframe:

Week 112

End point values	Tildrakizumab 100 mg (Extension Study)	Tildrakizumab 200 mg (extension study)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	245	188		
Units: Proportion of subjects				
number (not applicable)	0.849	0.835		

Statistical analyses

No statistical analyses for this end point

Secondary: Proportion of Subjects With PASI 90 Response Over Time Among PASI 90 Responders at Week 52 (Extension Study) at Week 172

End point title	Proportion of Subjects With PASI 90 Response Over Time Among PASI 90 Responders at Week 52 (Extension Study) at Week 172

End point description:

End point type	Secondary

End point timeframe:

Week 172

End point values	Tildrakizumab 100 mg (Extension Study)	Tildrakizumab 200 mg (extension study)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	234	178		
Units: Proportion of subjects				
number (not applicable)	0.812	0.815		

Statistical analyses

No statistical analyses for this end point

Secondary: Proportion of Subjects With PASI 90 Response Over Time Among PASI 90 Responders at Week 52 (Extension Study) at Week 220

End point title	Proportion of Subjects With PASI 90 Response Over Time Among PASI 90 Responders at Week 52 (Extension Study) at Week 220

End point description:

End point type	Secondary

End point timeframe:

Week 220

End point values	Tildrakizumab 100 mg (Extension Study)	Tildrakizumab 200 mg (extension study)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	218	171		
Units: Proportion of subjects				
number (not applicable)	0.807	0.766		

Statistical analyses

No statistical analyses for this end point

Secondary: Proportion of Subjects With PASI 90 Response Over Time Among PASI 90 Responders at Week 52 (Extension Study) Week 268

End point title	Proportion of Subjects With PASI 90 Response Over Time Among PASI 90 Responders at Week 52 (Extension Study) Week 268

End point description:

End point type	Secondary

End point timeframe:

Week 268

End point values	Tildrakizumab 100 mg (Extension Study)	Tildrakizumab 200 mg (extension study)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	75	53		
Units: Proportion of subjects				
number (not applicable)	0.853	0.736		

Statistical analyses

No statistical analyses for this end point

Secondary: Proportion of Subjects With PASI 90 Response Over Time Among PASI 90 Responders at Week 52 (Extension Study) at Week 316

End point title	Proportion of Subjects With PASI 90 Response Over Time Among PASI 90 Responders at Week 52 (Extension Study) at Week 316

End point description:

End point type	Secondary

End point timeframe:

Week 316

End point values	Tildrakizumab 100 mg (Extension Study)	Tildrakizumab 200 mg (extension study)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	38	20		
Units: Proportion of subjects				
number (not applicable)	0.816	0.8		

Statistical analyses

No statistical analyses for this end point

Secondary: Proportion of Subjects With PASI 90 Response Over Time Among PASI 90 Responders at Week 52 (Extension Study) at Week 364

End point title	Proportion of Subjects With PASI 90 Response Over Time Among PASI 90 Responders at Week 52 (Extension Study) at Week 364

End point description:

End point type	Secondary

End point timeframe:

Week 364

End point values	Tildrakizumab 100 mg (Extension Study)	Tildrakizumab 200 mg (extension study)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	10	6		
Units: Proportion of subjects				
number (not applicable)	0.9	1		

Statistical analyses

No statistical analyses for this end point

Secondary: Proportion of Subjects With PASI 90 Response Over Time Among PASI 90 Responders at Week 52 (Extension Study) at Week 396

End point title	Proportion of Subjects With PASI 90 Response Over Time Among PASI 90 Responders at Week 52 (Extension Study) at Week 396

End point description:

End point type	Secondary

End point timeframe:

Week 396

End point values	Tildrakizumab 100 mg (Extension Study)	Tildrakizumab 200 mg (extension study)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1	0[3]		
Units: Proportion of subjects				
number (not applicable)	1			

Notes:

[3] - No subjects were available for assessment at Week 396; therefore, zero subjects were analyzed.

Statistical analyses

No statistical analyses for this end point

Secondary: Proportion of Subjects With PASI 100 Response Over Time Among PASI 100 Responders at Week 52 (Extension Study) at Week 60

End point title	Proportion of Subjects With PASI 100 Response Over Time Among PASI 100 Responders at Week 52 (Extension Study) at Week 60

End point description:

End point type	Secondary

End point timeframe:

Week 60

End point values	Tildrakizumab 100 mg (Extension Study)	Tildrakizumab 200 mg (extension study)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	131	99		
Units: Proportion of subjects				
number (not applicable)	0.84	0.798		

Statistical analyses

No statistical analyses for this end point

Secondary: Proportion of Subjects With PASI 100 Response Over Time Among PASI 100 Responders at Week 52 (Extension Study) at Week 112

End point title	Proportion of Subjects With PASI 100 Response Over Time Among PASI 100 Responders at Week 52 (Extension Study) at Week 112

End point description:

End point type	Secondary

End point timeframe:

Week 112

End point values	Tildrakizumab 100 mg (Extension Study)	Tildrakizumab 200 mg (extension study)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	123	95		
Units: Proportion of subjects				
number (not applicable)	0.699	0.653		

Statistical analyses

No statistical analyses for this end point

Secondary: Proportion of Subjects With PASI 100 Response Over Time Among PASI 100 Responders at Week 52 (Extension Study) at Week 172

End point title	Proportion of Subjects With PASI 100 Response Over Time Among PASI 100 Responders at Week 52 (Extension Study) at Week 172

End point description:

End point type	Secondary

End point timeframe:

Week 172

End point values	Tildrakizumab 100 mg (Extension Study)	Tildrakizumab 200 mg (extension study)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	120	89		
Units: Proportion of subjects				
number (not applicable)	0.633	0.618		

Statistical analyses

No statistical analyses for this end point

Secondary: Proportion of Subjects With PASI 100 Response Over Time Among PASI 100 Responders at Week 52 (Extension Study) at Week 220

End point title	Proportion of Subjects With PASI 100 Response Over Time Among PASI 100 Responders at Week 52 (Extension Study) at Week 220

End point description:

End point type	Secondary

End point timeframe:

Week 220

End point values	Tildrakizumab 100 mg (Extension Study)	Tildrakizumab 200 mg (extension study)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	112	86		
Units: Proportion of subjects				
number (not applicable)	0.67	0.558		

Statistical analyses

No statistical analyses for this end point

Secondary: Proportion of Subjects With PASI 100 Response Over Time Among PASI 100 Responders at Week 52 (Extension Study) at Week 268

End point title	Proportion of Subjects With PASI 100 Response Over Time Among PASI 100 Responders at Week 52 (Extension Study) at Week 268

End point description:

End point type	Secondary

End point timeframe:

Week 268

End point values	Tildrakizumab 100 mg (Extension Study)	Tildrakizumab 200 mg (extension study)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	38	29		
Units: Proportion of subjects				
number (not applicable)	0.684	0.586		

Statistical analyses

No statistical analyses for this end point

Secondary: Proportion of Subjects With PASI 100 Response Over Time Among PASI 100 Responders at Week 52 (Extension Study) at Week 316

End point title	Proportion of Subjects With PASI 100 Response Over Time Among PASI 100 Responders at Week 52 (Extension Study) at Week 316

End point description:

End point type	Secondary

End point timeframe:

Week 316

End point values	Tildrakizumab 100 mg (Extension Study)	Tildrakizumab 200 mg (extension study)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	19	9		
Units: Proportion of subjects				
number (not applicable)	0.737	0.667		

Statistical analyses

No statistical analyses for this end point

Secondary: Proportion of Subjects With PASI 100 Response Over Time Among PASI 100 Responders at Week 52 (Extension Study) at Week 364

End point title	Proportion of Subjects With PASI 100 Response Over Time Among PASI 100 Responders at Week 52 (Extension Study) at Week 364

End point description:

End point type	Secondary

End point timeframe:

Week 364

End point values	Tildrakizumab 100 mg (Extension Study)	Tildrakizumab 200 mg (extension study)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	4	3		
Units: Proportion of subjects				
number (not applicable)	0.75	1		

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in Psoriasis Area and Severity Index Score Over Time (Extension Study) at Week 60

End point title	Change From Baseline in Psoriasis Area and Severity Index Score Over Time (Extension Study) at Week 60

End point description:

End point type	Secondary

End point timeframe:

Week 60

End point values	Tildrakizumab 100 mg (Extension Study)	Tildrakizumab 200 mg (extension study)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	376	344		
Units: score on a scale				
arithmetic mean (standard deviation)	-18.2 (± 7.53)	-17.3 (± 6.86)		

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in Psoriasis Area and Severity Index Score Over Time (Extension Study) at Week 112

End point title	Change From Baseline in Psoriasis Area and Severity Index Score Over Time (Extension Study) at Week 112

End point description:

End point type	Secondary

End point timeframe:

Week 112

End point values	Tildrakizumab 100 mg (Extension Study)	Tildrakizumab 200 mg (extension study)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	349	323		
Units: score on a scale				
arithmetic mean (standard deviation)	-17.8 (± 7.38)	-17.1 (± 6.79)		

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in Psoriasis Area and Severity Index Score Over Time (Extension Study) at Week 172

End point title	Change From Baseline in Psoriasis Area and Severity Index Score Over Time (Extension Study) at Week 172

End point description:

End point type	Secondary

End point timeframe:

Week 172

End point values	Tildrakizumab 100 mg (Extension Study)	Tildrakizumab 200 mg (extension study)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	320	295		
Units: score on a scale				
arithmetic mean (standard deviation)	-18.0 (± 7.16)	-17.1 (± 6.97)		

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in Psoriasis Area and Severity Index Score Over Time at Week 220(Extension Study)

End point title	Change From Baseline in Psoriasis Area and Severity Index Score Over Time at Week 220(Extension Study)

End point description:

End point type	Secondary

End point timeframe:

Week 220

End point values	Tildrakizumab 100 mg (Extension Study)	Tildrakizumab 200 mg (extension study)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	296	279		
Units: score on a scale				
arithmetic mean (standard deviation)	-18.0 (± 7.06)	-17.1 (± 6.73)		

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in Psoriasis Area and Severity Index Score Over Time (Extension Study) at Week 268

End point title	Change From Baseline in Psoriasis Area and Severity Index Score Over Time (Extension Study) at Week 268

End point description:

End point type	Secondary

End point timeframe:

Week 268

End point values	Tildrakizumab 100 mg (Extension Study)	Tildrakizumab 200 mg (extension study)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	103	85		
Units: score on a scale				
arithmetic mean (standard deviation)	-18.5 (± 6.87)	-18.0 (± 6.80)		

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in Psoriasis Area and Severity Index Score Over Time (Extension Study) at Week 316

End point title	Change From Baseline in Psoriasis Area and Severity Index Score Over Time (Extension Study) at Week 316

End point description:

End point type	Secondary

End point timeframe:

Week 316

End point values	Tildrakizumab 100 mg (Extension Study)	Tildrakizumab 200 mg (extension study)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	48	35		
Units: score on a scale				
arithmetic mean (standard deviation)	-18.0 (± 6.33)	-16.8 (± 4.30)		

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in Psoriasis Area and Severity Index Score Over Time (Extension Study) at Week 364

End point title	Change From Baseline in Psoriasis Area and Severity Index Score Over Time (Extension Study) at Week 364

End point description:

End point type	Secondary

End point timeframe:
Week 364

End point values	Tildrakizumab 100 mg (Extension Study)	Tildrakizumab 200 mg (extension study)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	11	9		
Units: score on a scale				
arithmetic mean (standard deviation)	-16.6 (± 3.80)	-19.5 (± 5.50)		

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Change From Baseline in Psoriasis Area and Severity Index Score Over Time (Extension Study) at Week 60

End point title	Percent Change From Baseline in Psoriasis Area and Severity Index Score Over Time (Extension Study) at Week 60

End point description:

End point type	Secondary

End point timeframe:
Week 60

End point values	Tildrakizumab 100 mg (Extension Study)	Tildrakizumab 200 mg (extension study)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	378	345		
Units: score on a scale				
arithmetic mean (standard deviation)	-91.4 (± 12.97)	-89.0 (± 13.11)		

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Change From Baseline in Psoriasis Area and Severity Index Score Over Time (Extension Study) at Week 112

End point title	Percent Change From Baseline in Psoriasis Area and Severity Index Score Over Time (Extension Study) at Week 112

End point description:

End point type	Secondary

End point timeframe:

Week 112

End point values	Tildrakizumab 100 mg (Extension Study)	Tildrakizumab 200 mg (extension study)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	349	323		
Units: score on a scale				
arithmetic mean (standard deviation)	-89.5 (± 14.67)	-88.3 (± 14.92)		

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Change From Baseline in Psoriasis Area and Severity Index Score Over Time (Extension Study) at Week 172

End point title	Percent Change From Baseline in Psoriasis Area and Severity Index Score Over Time (Extension Study) at Week 172

End point description:

End point type	Secondary

End point timeframe:

Week 172

End point values	Tildrakizumab 100 mg (Extension Study)	Tildrakizumab 200 mg (extension study)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	320	295		
Units: score on a scale				
arithmetic mean (standard deviation)	-90.9 (± 15.05)	-89.2 (± 14.61)		

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Change From Baseline in Psoriasis Area and Severity Index Score Over Time (Extension Study) at Week 220

End point title	Percent Change From Baseline in Psoriasis Area and Severity Index Score Over Time (Extension Study) at Week 220

End point description:

End point type	Secondary

End point timeframe:

Week 220

End point values	Tildrakizumab 100 mg (Extension Study)	Tildrakizumab 200 mg (extension study)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	296	279		
Units: score on a scale				
arithmetic mean (standard deviation)	-91.8 (± 11.49)	-89.7 (± 12.23)		

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Change From Baseline in Psoriasis Area and Severity Index Score Over Time (Extension Study) at Week 268

End point title	Percent Change From Baseline in Psoriasis Area and Severity Index Score Over Time (Extension Study) at Week 268

End point description:

End point type	Secondary

End point timeframe:

Week 268

End point values	Tildrakizumab 100 mg (Extension Study)	Tildrakizumab 200 mg (extension study)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	103	85		
Units: score on a scale				
arithmetic mean (standard deviation)	-92.3 (± 10.83)	-91.3 (± 10.72)		

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Change From Baseline in Psoriasis Area and Severity Index Score Over Time (Extension Study) at Week 316

End point title	Percent Change From Baseline in Psoriasis Area and Severity Index Score Over Time (Extension Study) at Week 316

End point description:

End point type	Secondary

End point timeframe:

Week 316

End point values	Tildrakizumab 100 mg (Extension Study)	Tildrakizumab 200 mg (extension study)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	48	35		
Units: score on a scale				
arithmetic mean (standard deviation)	-93.1 (± 10.34)	-94.8 (± 6.76)		

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Change From Baseline in Psoriasis Area and Severity Index Score Over Time (Extension Study) at Week 364

End point title	Percent Change From Baseline in Psoriasis Area and Severity Index Score Over Time (Extension Study) at Week 364

End point description:

End point type	Secondary

End point timeframe:

Week 364

End point values	Tildrakizumab 100 mg (Extension Study)	Tildrakizumab 200 mg (extension study)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	11	9		
Units: score on a scale				
arithmetic mean (standard deviation)	-95.9 (± 5.85)	-96.7 (± 7.32)		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants With a PGA Score of Clear or Minimal With at Least a 2 Grade Reduction From Baseline (Extension Study) at Week 60

End point title	Percentage of Participants With a PGA Score of Clear or Minimal With at Least a 2 Grade Reduction From Baseline (Extension Study) at Week 60

End point description:

End point type	Secondary

End point timeframe:

Week 60

End point values	Tildrakizumab 100 mg (Extension Study)	Tildrakizumab 200 mg (extension study)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	374	342		
Units: Percentage of Subjects				
number (not applicable)	74.1	70.8		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants With a PGA Score of Clear or Minimal With at Least a 2 Grade Reduction From Baseline (Extension Study) at Week 112

End point title	Percentage of Participants With a PGA Score of Clear or Minimal With at Least a 2 Grade Reduction From Baseline (Extension Study) at Week 112

End point description:

End point type	Secondary

End point timeframe:

Week 112

End point values	Tildrakizumab 100 mg (Extension Study)	Tildrakizumab 200 mg (extension study)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	346	320		
Units: Percentage of subjects				
number (not applicable)	63.9	65.3		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants With a PGA Score of Clear or Minimal With at Least a 2 Grade Reduction From Baseline (Extension Study) at Week 172

End point title	Percentage of Participants With a PGA Score of Clear or Minimal With at Least a 2 Grade Reduction From Baseline (Extension Study) at Week 172

End point description:

End point type	Secondary

End point timeframe:

Week 172

End point values	Tildrakizumab 100 mg (Extension Study)	Tildrakizumab 200 mg (extension study)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	316	292		
Units: Percentage of subjects				
number (not applicable)	70.3	62.3		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants With a PGA Score of Clear or Minimal With at Least a 2 Grade Reduction From Baseline (Extension Study) at Week 220

End point title	Percentage of Participants With a PGA Score of Clear or Minimal With at Least a 2 Grade Reduction From Baseline (Extension Study) at Week 220

End point description:

End point type	Secondary

End point timeframe:

Week 220

End point values	Tildrakizumab 100 mg (Extension Study)	Tildrakizumab 200 mg (extension study)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	292	275		
Units: Percentage of subjects				
number (not applicable)	73.3	64.4		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants With a PGA Score of Clear or Minimal With at Least a 2 Grade Reduction From Baseline (Extension Study) at Week 268

End point title	Percentage of Participants With a PGA Score of Clear or Minimal With at Least a 2 Grade Reduction From Baseline (Extension Study) at Week 268

End point description:

End point type	Secondary

End point timeframe:

Week 268

End point values	Tildrakizumab 100 mg (Extension Study)	Tildrakizumab 200 mg (extension study)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	101	84		
Units: Percentage of subjects				
number (not applicable)	75.2	69.0		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants With a PGA Score of Clear or Minimal With at Least a 2 Grade Reduction From Baseline (Extension Study) at Week 364

End point title	Percentage of Participants With a PGA Score of Clear or Minimal With at Least a 2 Grade Reduction From Baseline (Extension Study) at Week 364

End point description:

End point type	Secondary

End point timeframe:

Week 364

End point values	Tildrakizumab 100 mg (Extension Study)	Tildrakizumab 200 mg (extension study)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	11	9		
Units: Percentage of subjects				
number (not applicable)	72.7	88.9		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects With a PASI75 Response Over Time (Extension Study) at Week 60

End point title	Percentage of Subjects With a PASI75 Response Over Time (Extension Study) at Week 60

End point description:

End point type	Secondary

End point timeframe:

Week 60

End point values	Tildrakizumab 100 mg (Extension Study)	Tildrakizumab 200 mg (extension study)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	378	345		
Units: Percentage of subjects				
number (not applicable)	91.3	86.7		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects With a PASI75 Response Over Time (Extension

Study) at Week 112

End point title	Percentage of Subjects With a PASI75 Response Over Time (Extension Study) at Week 112

End point description:

End point type	Secondary

End point timeframe:

Week 112

End point values	Tildrakizumab 100 mg (Extension Study)	Tildrakizumab 200 mg (extension study)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	349	323		
Units: Percentage of subjects				
number (not applicable)	86.8	83.3		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects With a PASI75 Response Over Time (Extension Study) at Week 172

End point title	Percentage of Subjects With a PASI75 Response Over Time (Extension Study) at Week 172

End point description:

End point type	Secondary

End point timeframe:

Week 172

End point values	Tildrakizumab 100 mg (Extension Study)	Tildrakizumab 200 mg (extension study)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	320	295		
Units: Percentage of subjects				
number (not applicable)	91.3	86.1		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects With a PASI75 Response Over Time (Extension Study) at Week 220

End point title	Percentage of Subjects With a PASI75 Response Over Time (Extension Study) at Week 220

End point description:

End point type	Secondary

End point timeframe:

220

End point values	Tildrakizumab 100 mg (Extension Study)	Tildrakizumab 200 mg (extension study)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	296	279		
Units: Percentage of subjects				
number (not applicable)	90.2	86.7		

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Up to 52 weeks

Adverse event reporting additional description:

Part 1 includes all randomized participants who received at least 1 dose of Part 1 study drug, based on the treatment received. Part 2 includes all randomized participants who received at least 1 dose of Part 2 study drug, based on the treatment received, including those on placebo re-randomized at Week 12 to tildrakizumab. Part 3 includes all part

Assessment type	Systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	19.1

Reporting groups

Reporting group title	Placebo- Base study

Reporting group description:

Participants received matching placebo to tildrakizumab SC on Weeks 0 and 4.

Reporting group title	Etanercept 50 mg

Reporting group description:

Participants received etanercept 50 mg twice weekly up to Week 12 and once weekly from Week 12 to Week 28.

Reporting group title	Tildrakizumab 100 mg (Parts 1, 2 & 3)

Reporting group description:

Participants received tildrakizumab 100 mg SC on Weeks 0, 4 and then every 12 weeks.

Reporting group title	Tildrakizumab 200 mg (Parts 1, 2 & 3) Wk-28 R

Reporting group description:

Participants received tildrakizumab 200 mg SC on Weeks 0 and 4 (Part 1), Week 16 (Part 2), and Weeks 28 and 40 (Part 3) plus etanercept PBO twice weekly until Week 12 and once weekly from Week 12 to Week 28.

Reporting group title	Tildrakizumab 100 mg - Extension Study

Reporting group description: -

Reporting group title	Tildrakizumab 200 mg - Extension Study

Reporting group description: -

Serious adverse events	Placebo- Base study	Etanercept 50 mg	Tildrakizumab 100 mg (Parts 1, 2 & 3)
Total subjects affected by serious adverse events			
subjects affected / exposed	4 / 156 (2.56%)	20 / 313 (6.39%)	30 / 487 (6.16%)
number of deaths (all causes)	0	0	3
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Acute myeloid leukaemia			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	1 / 487 (0.21%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Bladder transitional cell carcinoma			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	1 / 487 (0.21%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bowen's disease			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	1 / 487 (0.21%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Breast cancer			
subjects affected / exposed	0 / 156 (0.00%)	1 / 313 (0.32%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung adenocarcinoma			
subjects affected / exposed	0 / 156 (0.00%)	1 / 313 (0.32%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malignant melanoma in situ			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	1 / 487 (0.21%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal oncocytoma			
subjects affected / exposed	0 / 156 (0.00%)	1 / 313 (0.32%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Squamous cell carcinoma of skin			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	1 / 487 (0.21%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thyroid cancer			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	1 / 487 (0.21%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Basal cell carcinoma			

subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bladder cancer			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Breast cancer metastatic			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colon cancer			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enchondromatosis			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatic adenoma			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lipoma			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malignant melanoma			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ovarian cancer			

subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Testicular neoplasm			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Uterine leiomyoma			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Peripheral arterial occlusive disease			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	1 / 487 (0.21%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Deep vein thrombosis			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertension			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertensive crisis			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Varicose vein			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Surgical and medical procedures			

Cataract			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
High frequency ablation			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pregnancy, puerperium and perinatal conditions			
Gestational diabetes			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Chest pain			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Death			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematoma			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Impaired healing			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Non-cardiac chest pain			

subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Breast cyst			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Adenomyosis			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Benign prostatic hyperplasia			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Uterine haemorrhage			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Uterovaginal prolapse			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Respiratory arrest			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	1 / 487 (0.21%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sleep apnoea syndrome			
subjects affected / exposed	0 / 156 (0.00%)	1 / 313 (0.32%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Asphyxia			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Asthma			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemothorax			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Laryngeal granuloma			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nasal septum deviation			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nasal turbinate hypertrophy			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Alcoholism			
subjects affected / exposed	0 / 156 (0.00%)	1 / 313 (0.32%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Bipolar disorder			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	1 / 487 (0.21%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Borderline personality disorder			
subjects affected / exposed	0 / 156 (0.00%)	1 / 313 (0.32%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Depression			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	2 / 487 (0.41%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Alcohol use disorder			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Completed suicide			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Drug dependence			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Insomnia			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Product issues			
Device dislocation			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			

Bile duct stone			
subjects affected / exposed	0 / 156 (0.00%)	1 / 313 (0.32%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholelithiasis			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	1 / 487 (0.21%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Steatohepatitis			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	1 / 487 (0.21%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholecystitis			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Blood glucose increased			
subjects affected / exposed	0 / 156 (0.00%)	1 / 313 (0.32%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transaminases increased			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Ankle fracture			
subjects affected / exposed	0 / 156 (0.00%)	1 / 313 (0.32%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Concussion			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Hand fracture			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	1 / 487 (0.21%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Humerus fracture			
subjects affected / exposed	0 / 156 (0.00%)	1 / 313 (0.32%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Meniscus injury			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	1 / 487 (0.21%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tendon rupture			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	1 / 487 (0.21%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bone contusion			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chest injury			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Facial bones fracture			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Foot fracture			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Incisional hernia			

subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ligament rupture			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Limb injury			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower limb fracture			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Multiple fractures			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Multiple injuries			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Patella fracture			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thoracic vertebral fracture			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Toxicity to various agents			

subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Traumatic intracranial haematoma			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wrist fracture			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Congenital, familial and genetic disorders			
Keratosis follicular			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Atrial fibrillation			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	2 / 487 (0.41%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial flutter			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	1 / 487 (0.21%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure congestive			
subjects affected / exposed	0 / 156 (0.00%)	1 / 313 (0.32%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Cardiomyopathy alcoholic			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	1 / 487 (0.21%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coronary artery disease			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coronary artery stenosis			
subjects affected / exposed	0 / 156 (0.00%)	1 / 313 (0.32%)	1 / 487 (0.21%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mitral valve incompetence			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocardial infarction			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	1 / 487 (0.21%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pericarditis			
subjects affected / exposed	1 / 156 (0.64%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute myocardial infarction			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial tachycardia			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrioventricular block second degree			

subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocardial ischaemia			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocarditis			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Supraventricular tachycardia			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Carotid artery stenosis			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Headache			
subjects affected / exposed	0 / 156 (0.00%)	1 / 313 (0.32%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Radiculopathy			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Seizure			
subjects affected / exposed	0 / 156 (0.00%)	1 / 313 (0.32%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transient ischaemic attack			

subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	1 / 487 (0.21%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Carpal tunnel syndrome			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebral ischaemia			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebrovascular accident			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dizziness			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epilepsy			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Facial paresis			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intensive care unit acquired weakness			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intracranial aneurysm			

subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ischaemic cerebral infarction			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ischaemic stroke			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lumbar radiculopathy			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	1 / 487 (0.21%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Optic ischaemic neuropathy			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Gastrointestinal disorders			
Abdominal hernia			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	1 / 487 (0.21%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspepsia			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	1 / 487 (0.21%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastritis			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	1 / 487 (0.21%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhoids thrombosed			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	1 / 487 (0.21%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophageal polyp			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	1 / 487 (0.21%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain upper			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulum intestinal			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Duodenal ulcer haemorrhage			

subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterocolitis			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastric perforation			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastric ulcer haemorrhage			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastritis erosive			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hiatus hernia			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inguinal hernia			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestine polyp			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malocclusion			

subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mesenteric artery thrombosis			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis acute			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Umbilical hernia			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Psoriasis			
subjects affected / exposed	0 / 156 (0.00%)	1 / 313 (0.32%)	1 / 487 (0.21%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Drug eruption			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Duodenal polyp			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Nephrolithiasis			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	1 / 487 (0.21%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Obstructive uropathy			

subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ureterolithiasis			
subjects affected / exposed	1 / 156 (0.64%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute kidney injury			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Calculus urinary			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cystitis noninfective			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocrine disorders			
Hyperthyroidism			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	1 / 487 (0.21%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Goitre			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thyrotoxic crisis			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			

Back pain			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	1 / 487 (0.21%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cervical spinal stenosis			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	1 / 487 (0.21%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intervertebral disc disorder			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intervertebral disc protrusion			
subjects affected / exposed	1 / 156 (0.64%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteoarthritis			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rotator cuff syndrome			
subjects affected / exposed	0 / 156 (0.00%)	1 / 313 (0.32%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spondylolisthesis			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteonecrosis			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bursitis			

subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intervertebral disc degeneration			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Patellofemoral pain syndrome			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Appendicitis			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	1 / 487 (0.21%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	1 / 156 (0.64%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulitis			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Erysipelas			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	1 / 487 (0.21%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Herpes zoster			
subjects affected / exposed	0 / 156 (0.00%)	1 / 313 (0.32%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			

subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sinusitis			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	1 / 487 (0.21%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urosepsis			
subjects affected / exposed	0 / 156 (0.00%)	1 / 313 (0.32%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound infection			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	1 / 487 (0.21%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal wall abscess			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic sinusitis			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device related sepsis			

subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epididymitis			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis bacterial			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infected dermal cyst			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestine infection			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Meningitis viral			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Otitis media acute			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peritonitis			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tonsillitis			

subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral infection			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Obesity			
subjects affected / exposed	0 / 156 (0.00%)	1 / 313 (0.32%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diabetes mellitus			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Jaw cyst			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Overweight			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tetany			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Type 2 diabetes mellitus			
subjects affected / exposed	0 / 156 (0.00%)	0 / 313 (0.00%)	0 / 487 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Tildrakizumab 200	Tildrakizumab 100	Tildrakizumab 200

	mg (Parts 1, 2 & 3) Wk-28 R	mg - Extension Study	mg - Extension Study
Total subjects affected by serious adverse events			
subjects affected / exposed	26 / 527 (4.93%)	87 / 381 (22.83%)	79 / 349 (22.64%)
number of deaths (all causes)	0	2	1
number of deaths resulting from adverse events	0		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Acute myeloid leukaemia			
subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bladder transitional cell carcinoma			
subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	1 / 349 (0.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bowen's disease			
subjects affected / exposed	0 / 527 (0.00%)	1 / 381 (0.26%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Breast cancer			
subjects affected / exposed	1 / 527 (0.19%)	0 / 381 (0.00%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung adenocarcinoma			
subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malignant melanoma in situ			
subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	1 / 349 (0.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal oncocytoma			
subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Squamous cell carcinoma of skin			
subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thyroid cancer			
subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Basal cell carcinoma			
subjects affected / exposed	0 / 527 (0.00%)	3 / 381 (0.79%)	4 / 349 (1.15%)
occurrences causally related to treatment / all	0 / 0	0 / 3	1 / 6
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bladder cancer			
subjects affected / exposed	0 / 527 (0.00%)	1 / 381 (0.26%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Breast cancer metastatic			
subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	1 / 349 (0.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colon cancer			
subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	1 / 349 (0.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enchondromatosis			
subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	1 / 349 (0.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatic adenoma			
subjects affected / exposed	0 / 527 (0.00%)	1 / 381 (0.26%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lipoma			

subjects affected / exposed	0 / 527 (0.00%)	1 / 381 (0.26%)	1 / 349 (0.29%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malignant melanoma			
subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	1 / 349 (0.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ovarian cancer			
subjects affected / exposed	0 / 527 (0.00%)	1 / 381 (0.26%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Testicular neoplasm			
subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	1 / 349 (0.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Uterine leiomyoma			
subjects affected / exposed	0 / 527 (0.00%)	2 / 381 (0.52%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Peripheral arterial occlusive disease			
subjects affected / exposed	0 / 527 (0.00%)	2 / 381 (0.52%)	1 / 349 (0.29%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Deep vein thrombosis			
subjects affected / exposed	0 / 527 (0.00%)	1 / 381 (0.26%)	1 / 349 (0.29%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertension			
subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	1 / 349 (0.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertensive crisis			

subjects affected / exposed	0 / 527 (0.00%)	1 / 381 (0.26%)	1 / 349 (0.29%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Varicose vein			
subjects affected / exposed	0 / 527 (0.00%)	2 / 381 (0.52%)	1 / 349 (0.29%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Surgical and medical procedures			
Cataract			
subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	2 / 349 (0.57%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
High frequency ablation			
subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	1 / 349 (0.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pregnancy, puerperium and perinatal conditions			
Gestational diabetes			
subjects affected / exposed	0 / 527 (0.00%)	1 / 381 (0.26%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Chest pain			
subjects affected / exposed	0 / 527 (0.00%)	1 / 381 (0.26%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Death			
subjects affected / exposed	0 / 527 (0.00%)	1 / 381 (0.26%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Haematoma			

subjects affected / exposed	0 / 527 (0.00%)	1 / 381 (0.26%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Impaired healing			
subjects affected / exposed	0 / 527 (0.00%)	1 / 381 (0.26%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Non-cardiac chest pain			
subjects affected / exposed	0 / 527 (0.00%)	1 / 381 (0.26%)	1 / 349 (0.29%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Breast cyst			
subjects affected / exposed	1 / 527 (0.19%)	0 / 381 (0.00%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Adenomyosis			
subjects affected / exposed	0 / 527 (0.00%)	1 / 381 (0.26%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Benign prostatic hyperplasia			
subjects affected / exposed	0 / 527 (0.00%)	1 / 381 (0.26%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Uterine haemorrhage			
subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	1 / 349 (0.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Uterovaginal prolapse			
subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	1 / 349 (0.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			

Respiratory arrest			
subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sleep apnoea syndrome			
subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Asphyxia			
subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	1 / 349 (0.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Asthma			
subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	1 / 349 (0.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	1 / 349 (0.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemothorax			
subjects affected / exposed	0 / 527 (0.00%)	1 / 381 (0.26%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Laryngeal granuloma			
subjects affected / exposed	0 / 527 (0.00%)	1 / 381 (0.26%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nasal septum deviation			
subjects affected / exposed	0 / 527 (0.00%)	1 / 381 (0.26%)	1 / 349 (0.29%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nasal turbinate hypertrophy			

subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	1 / 349 (0.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Alcoholism			
subjects affected / exposed	0 / 527 (0.00%)	1 / 381 (0.26%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bipolar disorder			
subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Borderline personality disorder			
subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Depression			
subjects affected / exposed	0 / 527 (0.00%)	2 / 381 (0.52%)	1 / 349 (0.29%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Alcohol use disorder			
subjects affected / exposed	0 / 527 (0.00%)	1 / 381 (0.26%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Completed suicide			
subjects affected / exposed	0 / 527 (0.00%)	2 / 381 (0.52%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 2	0 / 0
Drug dependence			
subjects affected / exposed	0 / 527 (0.00%)	1 / 381 (0.26%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Insomnia			

subjects affected / exposed	0 / 527 (0.00%)	1 / 381 (0.26%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Product issues			
Device dislocation			
subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	1 / 349 (0.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Bile duct stone			
subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholelithiasis			
subjects affected / exposed	0 / 527 (0.00%)	4 / 381 (1.05%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 5	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Steatohepatitis			
subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholecystitis			
subjects affected / exposed	0 / 527 (0.00%)	1 / 381 (0.26%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Blood glucose increased			
subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transaminases increased			
subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	1 / 349 (0.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Injury, poisoning and procedural complications			
Ankle fracture			
subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Concussion			
subjects affected / exposed	1 / 527 (0.19%)	0 / 381 (0.00%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hand fracture			
subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Humerus fracture			
subjects affected / exposed	0 / 527 (0.00%)	1 / 381 (0.26%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Meniscus injury			
subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	2 / 349 (0.57%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tendon rupture			
subjects affected / exposed	2 / 527 (0.38%)	1 / 381 (0.26%)	1 / 349 (0.29%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bone contusion			
subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	1 / 349 (0.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chest injury			
subjects affected / exposed	0 / 527 (0.00%)	1 / 381 (0.26%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Facial bones fracture			
subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	1 / 349 (0.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Foot fracture			
subjects affected / exposed	0 / 527 (0.00%)	1 / 381 (0.26%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Incisional hernia			
subjects affected / exposed	0 / 527 (0.00%)	1 / 381 (0.26%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ligament rupture			
subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	1 / 349 (0.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Limb injury			
subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	1 / 349 (0.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower limb fracture			
subjects affected / exposed	0 / 527 (0.00%)	1 / 381 (0.26%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Multiple fractures			
subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	1 / 349 (0.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Multiple injuries			
subjects affected / exposed	0 / 527 (0.00%)	1 / 381 (0.26%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Patella fracture			

subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	1 / 349 (0.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thoracic vertebral fracture			
subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	1 / 349 (0.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Toxicity to various agents			
subjects affected / exposed	0 / 527 (0.00%)	1 / 381 (0.26%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Traumatic intracranial haematoma			
subjects affected / exposed	0 / 527 (0.00%)	1 / 381 (0.26%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wrist fracture			
subjects affected / exposed	0 / 527 (0.00%)	1 / 381 (0.26%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Congenital, familial and genetic disorders			
Keratosis follicular			
subjects affected / exposed	0 / 527 (0.00%)	1 / 381 (0.26%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Atrial fibrillation			
subjects affected / exposed	2 / 527 (0.38%)	1 / 381 (0.26%)	1 / 349 (0.29%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial flutter			
subjects affected / exposed	1 / 527 (0.19%)	0 / 381 (0.00%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Cardiac failure			
subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure congestive			
subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	1 / 349 (0.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiomyopathy alcoholic			
subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coronary artery disease			
subjects affected / exposed	1 / 527 (0.19%)	2 / 381 (0.52%)	2 / 349 (0.57%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coronary artery stenosis			
subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	2 / 349 (0.57%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mitral valve incompetence			
subjects affected / exposed	1 / 527 (0.19%)	0 / 381 (0.00%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocardial infarction			
subjects affected / exposed	0 / 527 (0.00%)	1 / 381 (0.26%)	1 / 349 (0.29%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pericarditis			
subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute myocardial infarction			

subjects affected / exposed	0 / 527 (0.00%)	1 / 381 (0.26%)	3 / 349 (0.86%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Atrial tachycardia			
subjects affected / exposed	0 / 527 (0.00%)	1 / 381 (0.26%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrioventricular block second degree			
subjects affected / exposed	0 / 527 (0.00%)	1 / 381 (0.26%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocardial ischaemia			
subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	1 / 349 (0.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocarditis			
subjects affected / exposed	0 / 527 (0.00%)	1 / 381 (0.26%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Supraventricular tachycardia			
subjects affected / exposed	0 / 527 (0.00%)	1 / 381 (0.26%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Carotid artery stenosis			
subjects affected / exposed	1 / 527 (0.19%)	1 / 381 (0.26%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Headache			
subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	1 / 349 (0.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Radiculopathy			

subjects affected / exposed	1 / 527 (0.19%)	1 / 381 (0.26%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Seizure			
subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transient ischaemic attack			
subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Carpal tunnel syndrome			
subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	1 / 349 (0.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebral ischaemia			
subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	1 / 349 (0.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebrovascular accident			
subjects affected / exposed	0 / 527 (0.00%)	2 / 381 (0.52%)	1 / 349 (0.29%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dizziness			
subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	1 / 349 (0.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epilepsy			
subjects affected / exposed	0 / 527 (0.00%)	1 / 381 (0.26%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Facial paresis			

subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	1 / 349 (0.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intensive care unit acquired weakness			
subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	1 / 349 (0.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intracranial aneurysm			
subjects affected / exposed	0 / 527 (0.00%)	1 / 381 (0.26%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ischaemic cerebral infarction			
subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	1 / 349 (0.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ischaemic stroke			
subjects affected / exposed	0 / 527 (0.00%)	2 / 381 (0.52%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lumbar radiculopathy			
subjects affected / exposed	0 / 527 (0.00%)	1 / 381 (0.26%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope			
subjects affected / exposed	0 / 527 (0.00%)	1 / 381 (0.26%)	1 / 349 (0.29%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 527 (0.00%)	1 / 381 (0.26%)	1 / 349 (0.29%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ear and labyrinth disorders			

Vertigo			
subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Optic ischaemic neuropathy			
subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	1 / 349 (0.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal hernia			
subjects affected / exposed	1 / 527 (0.19%)	0 / 381 (0.00%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain			
subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspepsia			
subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastritis			
subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhoids thrombosed			
subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophageal polyp			
subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Abdominal pain upper			
subjects affected / exposed	0 / 527 (0.00%)	1 / 381 (0.26%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulum intestinal			
subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	1 / 349 (0.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Duodenal ulcer haemorrhage			
subjects affected / exposed	0 / 527 (0.00%)	1 / 381 (0.26%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterocolitis			
subjects affected / exposed	0 / 527 (0.00%)	1 / 381 (0.26%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastric perforation			
subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	1 / 349 (0.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastric ulcer haemorrhage			
subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	1 / 349 (0.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastritis erosive			
subjects affected / exposed	0 / 527 (0.00%)	1 / 381 (0.26%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hiatus hernia			
subjects affected / exposed	0 / 527 (0.00%)	1 / 381 (0.26%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inguinal hernia			

subjects affected / exposed	0 / 527 (0.00%)	1 / 381 (0.26%)	1 / 349 (0.29%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestine polyp			
subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	1 / 349 (0.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malocclusion			
subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	1 / 349 (0.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mesenteric artery thrombosis			
subjects affected / exposed	0 / 527 (0.00%)	1 / 381 (0.26%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis acute			
subjects affected / exposed	0 / 527 (0.00%)	1 / 381 (0.26%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Umbilical hernia			
subjects affected / exposed	0 / 527 (0.00%)	1 / 381 (0.26%)	1 / 349 (0.29%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Psoriasis			
subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Drug eruption			
subjects affected / exposed	0 / 527 (0.00%)	1 / 381 (0.26%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Duodenal polyp			

subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	1 / 349 (0.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Nephrolithiasis			
subjects affected / exposed	0 / 527 (0.00%)	1 / 381 (0.26%)	3 / 349 (0.86%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Obstructive uropathy			
subjects affected / exposed	1 / 527 (0.19%)	0 / 381 (0.00%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ureterolithiasis			
subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute kidney injury			
subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	1 / 349 (0.29%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Calculus urinary			
subjects affected / exposed	0 / 527 (0.00%)	2 / 381 (0.52%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cystitis noninfective			
subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	1 / 349 (0.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocrine disorders			
Hyperthyroidism			
subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Goitre			

subjects affected / exposed	0 / 527 (0.00%)	1 / 381 (0.26%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thyrotoxic crisis			
subjects affected / exposed	0 / 527 (0.00%)	1 / 381 (0.26%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cervical spinal stenosis			
subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intervertebral disc disorder			
subjects affected / exposed	1 / 527 (0.19%)	0 / 381 (0.00%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intervertebral disc protrusion			
subjects affected / exposed	0 / 527 (0.00%)	3 / 381 (0.79%)	2 / 349 (0.57%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteoarthritis			
subjects affected / exposed	1 / 527 (0.19%)	1 / 381 (0.26%)	1 / 349 (0.29%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rotator cuff syndrome			
subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spondylolisthesis			

subjects affected / exposed	1 / 527 (0.19%)	1 / 381 (0.26%)	1 / 349 (0.29%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteonecrosis			
subjects affected / exposed	1 / 527 (0.19%)	0 / 381 (0.00%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bursitis			
subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	1 / 349 (0.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intervertebral disc degeneration			
subjects affected / exposed	0 / 527 (0.00%)	1 / 381 (0.26%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Patellofemoral pain syndrome			
subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	1 / 349 (0.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Appendicitis			
subjects affected / exposed	0 / 527 (0.00%)	3 / 381 (0.79%)	2 / 349 (0.57%)
occurrences causally related to treatment / all	0 / 0	1 / 3	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	1 / 527 (0.19%)	1 / 381 (0.26%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulitis			
subjects affected / exposed	2 / 527 (0.38%)	3 / 381 (0.79%)	2 / 349 (0.57%)
occurrences causally related to treatment / all	0 / 2	1 / 3	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Erysipelas			

subjects affected / exposed	0 / 527 (0.00%)	1 / 381 (0.26%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Herpes zoster			
subjects affected / exposed	1 / 527 (0.19%)	0 / 381 (0.00%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	1 / 527 (0.19%)	2 / 381 (0.52%)	1 / 349 (0.29%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis			
subjects affected / exposed	1 / 527 (0.19%)	0 / 381 (0.00%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	1 / 527 (0.19%)	0 / 381 (0.00%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sinusitis			
subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urosepsis			
subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound infection			
subjects affected / exposed	1 / 527 (0.19%)	0 / 381 (0.00%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal wall abscess			

subjects affected / exposed	0 / 527 (0.00%)	1 / 381 (0.26%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic sinusitis			
subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	1 / 349 (0.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device related sepsis			
subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	1 / 349 (0.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epididymitis			
subjects affected / exposed	0 / 527 (0.00%)	1 / 381 (0.26%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis bacterial			
subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	1 / 349 (0.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infected dermal cyst			
subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	1 / 349 (0.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestine infection			
subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	1 / 349 (0.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Meningitis viral			
subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	1 / 349 (0.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Otitis media acute			

subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	1 / 349 (0.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peritonitis			
subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	1 / 349 (0.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tonsillitis			
subjects affected / exposed	0 / 527 (0.00%)	1 / 381 (0.26%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral infection			
subjects affected / exposed	0 / 527 (0.00%)	1 / 381 (0.26%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Obesity			
subjects affected / exposed	0 / 527 (0.00%)	1 / 381 (0.26%)	1 / 349 (0.29%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diabetes mellitus			
subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	1 / 349 (0.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Jaw cyst			
subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	1 / 349 (0.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Overweight			
subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	1 / 349 (0.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tetany			

subjects affected / exposed	0 / 527 (0.00%)	0 / 381 (0.00%)	1 / 349 (0.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Type 2 diabetes mellitus			
subjects affected / exposed	0 / 527 (0.00%)	1 / 381 (0.26%)	0 / 349 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Placebo- Base study	Etanercept 50 mg	Tildrakizumab 100 mg (Parts 1, 2 & 3)
Total subjects affected by non-serious adverse events			
subjects affected / exposed	23 / 156 (14.74%)	118 / 313 (37.70%)	151 / 487 (31.01%)
Vascular disorders			
Hypertension			
subjects affected / exposed	5 / 156 (3.21%)	9 / 313 (2.88%)	17 / 487 (3.49%)
occurrences (all)	5	9	17
Nervous system disorders			
Headache			
subjects affected / exposed	6 / 156 (3.85%)	18 / 313 (5.75%)	29 / 487 (5.95%)
occurrences (all)	6	31	46
General disorders and administration site conditions			
Injection site erythema			
subjects affected / exposed	1 / 156 (0.64%)	28 / 313 (8.95%)	5 / 487 (1.03%)
occurrences (all)	2	98	5
Injection site reaction			
subjects affected / exposed	1 / 156 (0.64%)	17 / 313 (5.43%)	2 / 487 (0.41%)
occurrences (all)	1	54	2
Pyrexia			
subjects affected / exposed	2 / 156 (1.28%)	5 / 313 (1.60%)	10 / 487 (2.05%)
occurrences (all)	3	5	11
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	2 / 156 (1.28%)	8 / 313 (2.56%)	22 / 487 (4.52%)
occurrences (all)	2	11	24
Nausea			

subjects affected / exposed	1 / 156 (0.64%)	3 / 313 (0.96%)	15 / 487 (3.08%)
occurrences (all)	1	5	16
Toothache			
subjects affected / exposed	1 / 156 (0.64%)	4 / 313 (1.28%)	12 / 487 (2.46%)
occurrences (all)	1	5	12
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	3 / 156 (1.92%)	8 / 313 (2.56%)	14 / 487 (2.87%)
occurrences (all)	3	8	15
Oropharyngeal pain			
subjects affected / exposed	3 / 156 (1.92%)	8 / 313 (2.56%)	8 / 487 (1.64%)
occurrences (all)	3	8	8
Skin and subcutaneous tissue disorders			
Pruritus			
subjects affected / exposed	3 / 156 (1.92%)	11 / 313 (3.51%)	11 / 487 (2.26%)
occurrences (all)	3	23	11
Psoriasis			
subjects affected / exposed	4 / 156 (2.56%)	11 / 313 (3.51%)	5 / 487 (1.03%)
occurrences (all)	4	11	5
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	3 / 156 (1.92%)	10 / 313 (3.19%)	26 / 487 (5.34%)
occurrences (all)	3	13	30
Osteoarthritis			
subjects affected / exposed	0 / 156 (0.00%)	1 / 313 (0.32%)	0 / 487 (0.00%)
occurrences (all)	0	1	0
Back pain			
subjects affected / exposed	3 / 156 (1.92%)	9 / 313 (2.88%)	21 / 487 (4.31%)
occurrences (all)	3	10	22
Pain in extremity			
subjects affected / exposed	2 / 156 (1.28%)	3 / 313 (0.96%)	15 / 487 (3.08%)
occurrences (all)	2	3	15
Infections and infestations			
Nasopharyngitis			
subjects affected / exposed	12 / 156 (7.69%)	63 / 313 (20.13%)	112 / 487 (23.00%)
occurrences (all)	14	79	152

Upper respiratory tract infection			
subjects affected / exposed	1 / 156 (0.64%)	11 / 313 (3.51%)	15 / 487 (3.08%)
occurrences (all)	1	14	18
Bronchitis			
subjects affected / exposed	0 / 156 (0.00%)	5 / 313 (1.60%)	14 / 487 (2.87%)
occurrences (all)	0	5	15
Influenza			
subjects affected / exposed	3 / 156 (1.92%)	5 / 313 (1.60%)	12 / 487 (2.46%)
occurrences (all)	3	5	15
Sinusitis			
subjects affected / exposed	1 / 156 (0.64%)	4 / 313 (1.28%)	20 / 487 (4.11%)
occurrences (all)	1	7	22
Urinary tract infection			
subjects affected / exposed	4 / 156 (2.56%)	12 / 313 (3.83%)	8 / 487 (1.64%)
occurrences (all)	4	13	8
Gastroenteritis			
subjects affected / exposed	1 / 156 (0.64%)	8 / 313 (2.56%)	10 / 487 (2.05%)
occurrences (all)	1	8	11
Rhinitis			
subjects affected / exposed	1 / 156 (0.64%)	5 / 313 (1.60%)	8 / 487 (1.64%)
occurrences (all)	1	5	10
Pharyngitis			
subjects affected / exposed	1 / 156 (0.64%)	4 / 313 (1.28%)	9 / 487 (1.85%)
occurrences (all)	1	4	10

Non-serious adverse events	Tildrakizumab 200 mg (Parts 1, 2 & 3) Wk-28 R	Tildrakizumab 100 mg - Extension Study	Tildrakizumab 200 mg - Extension Study
Total subjects affected by non-serious adverse events			
subjects affected / exposed	167 / 527 (31.69%)	344 / 381 (90.29%)	333 / 349 (95.42%)
Vascular disorders			
Hypertension			
subjects affected / exposed	12 / 527 (2.28%)	49 / 381 (12.86%)	59 / 349 (16.91%)
occurrences (all)	12	55	77
Nervous system disorders			
Headache			
subjects affected / exposed	30 / 527 (5.69%)	37 / 381 (9.71%)	44 / 349 (12.61%)
occurrences (all)	40	77	76

General disorders and administration site conditions			
Injection site erythema			
subjects affected / exposed	5 / 527 (0.95%)	7 / 381 (1.84%)	15 / 349 (4.30%)
occurrences (all)	7	7	42
Injection site reaction			
subjects affected / exposed	4 / 527 (0.76%)	7 / 381 (1.84%)	5 / 349 (1.43%)
occurrences (all)	8	13	5
Pyrexia			
subjects affected / exposed	3 / 527 (0.57%)	19 / 381 (4.99%)	8 / 349 (2.29%)
occurrences (all)	3	20	8
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	20 / 527 (3.80%)	45 / 381 (11.81%)	35 / 349 (10.03%)
occurrences (all)	25	63	49
Nausea			
subjects affected / exposed	11 / 527 (2.09%)	20 / 381 (5.25%)	14 / 349 (4.01%)
occurrences (all)	12	27	17
Toothache			
subjects affected / exposed	8 / 527 (1.52%)	23 / 381 (6.04%)	11 / 349 (3.15%)
occurrences (all)	8	27	11
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	19 / 527 (3.61%)	34 / 381 (8.92%)	28 / 349 (8.02%)
occurrences (all)	20	34	28
Oropharyngeal pain			
subjects affected / exposed	14 / 527 (2.66%)	24 / 381 (6.30%)	23 / 349 (6.59%)
occurrences (all)	15	31	30
Skin and subcutaneous tissue disorders			
Pruritus			
subjects affected / exposed	15 / 527 (2.85%)	17 / 381 (4.46%)	26 / 349 (7.45%)
occurrences (all)	18	22	40
Psoriasis			
subjects affected / exposed	4 / 527 (0.76%)	23 / 381 (6.04%)	14 / 349 (4.01%)
occurrences (all)	5	26	17
Musculoskeletal and connective tissue disorders			

Arthralgia			
subjects affected / exposed	14 / 527 (2.66%)	51 / 381 (13.39%)	65 / 349 (18.62%)
occurrences (all)	17	70	98
Osteoarthritis			
subjects affected / exposed	6 / 527 (1.14%)	15 / 381 (3.94%)	18 / 349 (5.16%)
occurrences (all)	6	17	19
Back pain			
subjects affected / exposed	19 / 527 (3.61%)	46 / 381 (12.07%)	46 / 349 (13.18%)
occurrences (all)	19	52	55
Pain in extremity			
subjects affected / exposed	6 / 527 (1.14%)	19 / 381 (4.99%)	13 / 349 (3.72%)
occurrences (all)	7	27	16
Infections and infestations			
Nasopharyngitis			
subjects affected / exposed	119 / 527 (22.58%)	186 / 381 (48.82%)	168 / 349 (48.14%)
occurrences (all)	174	471	472
Upper respiratory tract infection			
subjects affected / exposed	27 / 527 (5.12%)	41 / 381 (10.76%)	47 / 349 (13.47%)
occurrences (all)	30	75	83
Bronchitis			
subjects affected / exposed	20 / 527 (3.80%)	34 / 381 (8.92%)	43 / 349 (12.32%)
occurrences (all)	21	49	65
Influenza			
subjects affected / exposed	16 / 527 (3.04%)	35 / 381 (9.19%)	41 / 349 (11.75%)
occurrences (all)	18	50	51
Sinusitis			
subjects affected / exposed	15 / 527 (2.85%)	36 / 381 (9.45%)	25 / 349 (7.16%)
occurrences (all)	16	58	43
Urinary tract infection			
subjects affected / exposed	10 / 527 (1.90%)	30 / 381 (7.87%)	28 / 349 (8.02%)
occurrences (all)	12	44	42
Gastroenteritis			
subjects affected / exposed	9 / 527 (1.71%)	30 / 381 (7.87%)	27 / 349 (7.74%)
occurrences (all)	9	37	30
Rhinitis			

subjects affected / exposed	10 / 527 (1.90%)	21 / 381 (5.51%)	21 / 349 (6.02%)
occurrences (all)	10	38	34
Pharyngitis			
subjects affected / exposed	4 / 527 (0.76%)	20 / 381 (5.25%)	11 / 349 (3.15%)
occurrences (all)	5	22	17

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
27 January 2013	Revised Objectives and endpoints
11 January 2016	Other secondary objectives and secondary efficacy endpoints revised
24 July 2018	Trial objectives, other secondary trial objectives modified

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported